Sun Pharma Expands Innovative Portfolio with Lerodalcibep Licensing

Sun Pharma will license lerodalcibep for markets outside the US and China, targeting the high-growth cardiovascular sector.

Reader Takeaway: Strategic entry into a 38% CAGR market; success now hinges on navigating regulatory filings in new territories.

What just happened

Sun Pharmaceutical Industries has secured an exclusive agreement with LIB Therapeutics to commercialize and manufacture the PCSK9 inhibitor lerodalcibep. The deal covers all global regions excluding the US and China. The drug, which recently received EU approval, is positioned as a novel treatment for primary hypercholesterolaemia and mixed dyslipidaemia.

Why this matters

The global PCSK9 inhibitor market is valued at approximately US$ 7 billion, with the target territories outside the US and China accounting for US$ 3.7 billion as of Q2 2026. By integrating this into its Innovative Medicines portfolio—which currently makes up 22% of the company's sales—Sun Pharma is diversifying its revenue base with a specialized biologic therapy.

Product Differentiation

Lerodalcibep stands out due to its patient-friendly profile. It features a once-monthly 300 mg subcutaneous injection and allows for storage at room temperature for up to six months. These logistics advantages simplify the treatment process for patients compared to traditional cold-chain requirements.

Risks to watch

While the drug is approved in the EU, Sun Pharma faces execution risk in securing regulatory clearances in other licensed territories. Additionally, because the specific upfront, milestone, and royalty payments remain confidential, the exact margin impact on near-term financials remains difficult to quantify for retail investors.

What to track next

Investors should monitor the company's progress on regulatory filings in new regions and the subsequent commercial rollout of Lyrokaul. The speed of market penetration will be a key performance indicator for the cardiovascular segment.